Big bets being placed on Tmunity Therapeutics

If the $100 million total raised by Tmunity Therapeutics in a Series A financing is not evidence enough that it could be a significant mover in the T-cell immunotherapies space, then the clout of its investors should be a definite clue.

Set up by Carl June and his colleagues at the University of Pennsylvania and with former Novartis (NOVN: VX) heavyweight Usman ‘Oz’ Azam as chief executive, Tmunity is a private, clinical-stage biotherapeutics company focused on delivering the full potential of next-generation T-cell immunotherapy.

"Tmunity is unlike any other cell-based immunotherapy ‘start-up’ because of the unrivaled expertise of its scientific founders and leadership team in cell and gene therapy and its proven translational and manufacturing success in T-cell medicine"